doi: 10.1161/01.RES.0000241056.84659.59
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 American Heart Association, Inc.
Editorials |
Estrogen and Different Aspects of Vascular Disease in Women and Men
From the Division of Cardiovascular Medicine, University of Florida College of Medicine
Correspondence to Carl J. Pepine, MD, Division of Cardiovascular Medicine, University of Florida College of Medicine, 1600 SW Archer Road/Box 100277, Gainesville, FL 32610-0277. E-mail pepincj{at}medicine.ufl.edu
See related article, pages 477–484
Key Words: estrogen receptor-alpha (ESR1) • estrogen receptor-alpha genotype (ESR1) • gender-related vascular disease • women and vascular disease • men and vascular disease • vascular structure and function
 |
Introduction |
|---|
 Top Introduction Differences in Vascular Disease...Clinical Characteristics and...Estrogen and Sex/Gender-Related...References |
|---|
Considerable evidence indicates that sex hormones have an important influence on cardiovascular physiology and pathology.1,2 Recent work suggests that a mechanism based on estrogen receptor-alpha (ESR1) contributes to a range of structural and functional responses that relate to vascular disease. Most of this work focuses on ESR1 activity within the endothelium and yields variable findings due, at least in part, to differences in the vascular bed or species studied, as well as other experimental conditions such as age, estrogen status, degree of preconstriction, etc. But many findings in conduit arteries (eg, more frequent plaque erosion, increased wall stiffness, spasm, etc) and microvessels (eg, reduced coronary flow reserve, hot flashes, etc) implicate smooth muscle cells (SMCs) in gender differences in vascular disease. These cells are directly responsible for extracellular matrix production and assure the integrity of the artery wall. They may be decreased, apoptotic, or dysfunctional in terms of synthesis and repair of extracellular matrix, which is destroyed in vulnerable plaque by macrophages.
In this issue of Circulation Research Montague and colleagues3 report that activation of ESR1 decreases human aorta SMC differentiation (Figure). Importantly, they found that SMCs of men, compared with women, had reduced ESR1 expression associated with increased differentiation markers. Their work suggests that ESR1 activation switches SMC to a form that may promote plaque vulnerability. Could different activational states of ESR1 be responsible for shifting the functional characteristics of SMCs toward a phenotype that explains some complexities of gender-related differences in vascular disease?
|
|
Differences in Vascular Disease Between Women and Men |
|---|
|
TopIntroductionDifferences in Vascular Disease...Clinical Characteristics and...Estrogen and Sex/Gender-Related...References |
|---|
Risk conditions and clinical findings indicate that the pathophysiology underlying ischemic vascular disease differs between women and men.4 A number of conditions are unique to women (eg, early age at menopause, hypertensive disorders of pregnancy, gestational diabetes, peripartum aortic or coronary dissection, polycystic ovarian syndrome, hypothalamic hypoestrogenemia, etc). Other factors linked with vascular disease or dysfunction are much more frequent in women than men (eg, migraine, coronary spasm, vasculitis, Raynaud phenomenon, etc). On this background, postmenopausal women more frequently have many traditional vascular disease risk conditions (eg, diabetes, obesity, hypertension, inactivity, etc) which occur and cluster more frequently in women than men. In addition to this greater burden of risk factors, the woman with vascular disease often is older and has more functional disability than her male counterpart.5,6 Women have poor clinical outcomes compared with men with acute coronary syndromes,7 chronic coronary syndromes,8 coronary revascularization,9 and heart failure10 that cannot be explained by simply adjusting for age. So other factors must contribute to the increased severity of vascular disease in women compared with men.
|
Clinical Characteristics and Links With Sex Hormones |
|---|
|
TopIntroductionDifferences in Vascular Disease...Clinical Characteristics and...Estrogen and Sex/Gender-Related...References |
|---|
Although, ischemic vascular disease is the most frequent cause of death for women, its prevalence in women compared with men does not increase markedly until after menopause when major changes in sex hormones occur. During menopause estrogen levels are about one-tenth premenopausal levels and the predominant source, estradiol, changes to estrone produced by conversion of androgens in adipose tissue.1,6 Age-dependent aromatase expression in SMCs provides a mechanism for local production of estrogens from androgens.11 Aging attenuates many estrogen-related potentially beneficial responses.12 Yet, we have observed that central-induced endogenous estrogen deficiency in younger women is associated with a >7-fold increase in risk of coronary obstruction.13 One interpretation is the widely varying estrogen/androgen balance occurring throughout a woman’s life contributes to differences in vascular disease compared with men. This includes high levels of estrogen premenopause and decreasing estrogen and progesterone levels postmenopause, along with changing hormone balance during pregnancy, peripartum, and oral contraceptive or replacement therapy. Such varying estrogen/androgen balance interacts with the female unique and traditional risk conditions, as well as diet (eg, phytoestrogens, etc), physical activity, psychosocial characteristics, etc, to modulate differences in vascular disease.
Estrogen exerts effects via 2 receptors abundant in vascular tissue to transduce signals regulating expression of many genes, and it also has nongenomic effects.1 Considerable evidence implicates the ESR1 in vascular structure and function. Attempts to link estrogen receptor-alpha gene (ESR1) variation with adverse outcomes yield mixed results.14–19 Recently an overview of 5 studies including >7000 men suggested a 44% excess risk of myocardial infarction associated with the CC genotype at ESR1 c454–397T>C,20 strengthening the finding of an almost 2-fold increased risk of stroke associated with this CC genotype among 2709 of these men.21 Yet a study in 3404 postmenopausal women provided no evidence for an association of ESR1 genotypes or haplotypes with vascular outcomes.22 In light of Montague and colleagues’3 work, could variation in activation of ESR1 and changes in SMCs explain this link with vascular outcomes among men but not women? Clearly a better understanding is needed of the characteristics of SMCs of women and men among various phenotypes of ischemic vascular disease or ideally even before vascular disease becomes clinically apparent.
|
Estrogen and Sex/Gender-Related Differences in Blood Vessels |
|---|
|
TopIntroductionDifferences in Vascular Disease...Clinical Characteristics and...Estrogen and Sex/Gender-Related...References |
|---|
Women have smaller and stiffer conduit arteries than men even when adjusted for height, weight, and arterial pressure,23,24 contributing to earlier return of reflected arterial pulse waves, widened pulse pressure, and adverse effects on myocardial oxygen supply and demand. We found brachial pulse pressure to be the best independent predictor of cardiovascular adverse outcomes among blood pressure measures,25 suggesting that elastic properties of conduit arteries are important in the vasculopathy of women.
Changes in artery size (eg, remodeling) may occur in response to physiologic (eg, pregnancy, exercise, etc) or pathologic (eg, atherosclerosis, hypertension, etc) stimuli. Insight into potentially pathologic gender-related differences in remodeling comes from cardiac transplant recipients and transgender patients. Female hearts transplanted to females show little change in coronary size over time.26 But female hearts transplanted to males show progressive coronary enlargement, independent of body size and left ventricular hypertrophy, that persist over time. Links between sex hormones and differences in arterial size are strengthened by studies of transsexuals where brachial artery size in genetic males taking estrogens is smaller compared with control males.27,28 Genetic females taking androgens have larger arteries than control females.29 Androgen-deprivation therapy in genetic males is associated with smaller brachial artery size compared with control males.30 These findings support the notion that sex hormone balance has different, and under certain circumstances opposite, effects on conduit artery remodeling with an androgen state causing positive remodeling compared with an estrogen state. Positive remodeling is not invariably a compensating response and is also a marker of vascular disease.31 Positive remodeling as a marker for plaque vulnerable to rupture or erosion could be linked with the high event rate observed among women with normal or non-obstructive coronary angiographic findings.32–34
The findings of Montague et al3 of differential effects of ESR1 activation on SMC function advance our understanding the role of estrogen in regulation of vascular physiology and pathology. These findings should shed light on the complexities of gender-related vascular disease.
|
Acknowledgments |
|---|
Sources of Funding
This work was supported by contracts from the National Heart, Lung, and Blood Institutes, nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, grants U0164829, U01 HL649141, U01 HL649241, a GCRC grant MO1-RR00425 from the National Center for Research Resources, and grants from the Gustavus and Louis Pfeiffer Research Foundation, Denville, New Jersey, The Women’s Guild of Cedars-Sinai Medical Center, Los Angeles, California, The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, Pennsylvania, and QMED, Inc, Laurence Harbor, New Jersey.
Disclosures
None.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionDifferences in Vascular Disease...Clinical Characteristics and...Estrogen and Sex/Gender-Related...References |
|---|
1. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004; 286: R233–R249.
2. Pepine CJ. Ischemic heart disease in women: facts and wishful thinking. J Am Coll Cardiol. 2004; 43: 1727–1730.
3. Montague CR, Hunter MG, Gavrilin MA, Phillips GS, Goldschmidt-Clermont PJ, Marsh CB. Activation of estrogen receptor-a reduces aortic smooth muscle differentiation. Circ Res. 2006; 99: 477–484.
4. Pepine CJ, Kerensky RA, Lambert CR, Smith KM, von Mering GO, Sopko G, Bairey Merz CN. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol. 2006; 47: S30–S35.
5. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Pepine CJ, Mankad S, Sharaf BL, Rogers WJ, Pohost GM, Lerman A, Quyyumi AA, Sopko G. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol. 2006; 47: S21–S29.
6. Shaw LJ, Bairey Merz CN, Pepine CJ, Reis SE, Bittner V, Kelsey SF, Olson M, Johnson BD, Mankad S, Sharaf BL, Rogers WJ, Wessel TR, Arant CB, Pohost GM, Lerman A, Quyyumi AA, Sopko G. Insights from the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006; 47: S4–S20.
7. Vaccarino V, Parsons L, Every NR, Barron HV, Krumholz HM. Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N Engl J Med. 1999; 341: 217–225.
8. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Gender differences in the management and clinical outcome of stable angina. Circulation. 2006; 113: 490–498.
9. Humphries KH, Gao M, Lichtenstein SV, Thompson CR. Mortality in women after coronary artery bypass surgery really is higher. Circulation. 2005; 111: E42–E43.
10. Philbin EF, DiSalvo TG. Influence of race and gender on care process, resource use, and hospital-based outcomes in congestive heart failure. Am J Cardiol. 1998; 82: 76–81.[CrossRef][Medline] [Order article via Infotrieve]
11. Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H, Takagi Y. Localized expression of aromatase in human vascular tissues. Circ Res. 1999; 84: 1285–1291.
12. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003; 348: 593–600.
13. Bairey Merz CN, Johnson BD, Sharaf BL, Bittner V, Berga SL, Braunstein GD, Hodgson TK, Matthews KA, Pepine CJ, Reis SE, Reichek N, Rogers WJ, Pohost GM, Kelsey SF, Sopko G. Hypoestrogenemia of hypothalamic origin and coronary artery disease in premenopausal women: a report from the NHLBI-sponsored WISE study. J Am Coll Cardiol. 2003; 41: 413–419.
14. Herrington DM, Howard TD, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Brosnihan KB, Meyers DA, Bleecker ER. Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N Engl J Med. 2002; 346: 967–974.
15. Lehtimaki T, Kunnas TA, Mattila KM, Perola M, Penttila A, Koivula T, Karhunen PJ. Coronary artery wall atherosclerosis in relation to the estrogen receptor 1 gene polymorphism: an autopsy study. J Mol Med. 2002; 80: 176–180.[CrossRef][Medline] [Order article via Infotrieve]
16. Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER. Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation. 2002; 105: 1879–1882.
17. Koivu TA, Fan YM, Mattila KM, Dastidar P, Jokela H, Nikkari ST, Kunnas T, Punnonen R, Lehtimaki T. The effect of hormone replacement therapy on atherosclerotic severity in relation to ESR1 genotype in postmenopausal women. Maturitas. 2003; 44: 29–38.[CrossRef][Medline] [Order article via Infotrieve]
18. Shearman AM, Cupples LA, Demissie S, Peter I, Schmid CH, Karas RH, Mendelsohn ME, Housman DE, Levy D. Association between estrogen receptor alpha gene variation and cardiovascular disease. J Am Med Assoc. 2003; 290: 2263–2270.
19. Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG. Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. J Am Med Assoc. 2004; 291: 2969–2977.
20. Shearman AM, Cooper JA, Kotwinski PJ, Miller GJ, Humphries SE, Ardlie KG, Jordan B, Irenze K, Lunetta KL, Schuit SC, Uitterlinden AG, Pols HA, Demissie S, Cupples LA, Mendelsohn ME, Levy D, Housman DE. Estrogen receptor alpha gene variation is associated with risk of myocardial infarction in more than seven thousand men from five cohorts. Circ Res. 2006; 98: 590–592.
21. Shearman AM, Cooper JA, Kotwinski PJ, Humphries SE, Mendelsohn ME, Housman DE, Miller GJ. Estrogen receptor alpha gene variation and the risk of stroke. Stroke. 2005; 36: 2281–2282.
22. Lawlor DA, Timpson N, Ebrahim S, Day IN, Smith GD. The association of oestrogen receptor {alpha}-haplotypes with cardiovascular risk factors in the British Women’s Heart and Health Study. Eur Heart J. 2006; 27: 1597–1604.
23. Gatzka CD, Kingwell BA, Cameron JD, Berry KL, Liang YL, Dewar EM, Reid CM, Jennings GL, Dart AM. Gender differences in the timing of arterial wave reflection beyond differences in body height. J Hypertens. 2001; 19: 2197–2203.[CrossRef][Medline] [Order article via Infotrieve]
24. Sheifer SE, Canos MR, Weinfurt KP, Arora UK, Mendelsohn FO, Gersh BJ, Weissman NJ. Sex differences in coronary artery size assessed by intravascular ultrasound. Am Heart J. 2000; 139: 649–653.[Medline] [Order article via Infotrieve]
25. Sizemore BC, Barrow G, Johnson BD, Kip K, von Mering GO, Kerensky RA, Handberg E, Pepine CJ Pulse pressure is a stronger predictor of mortality and cardiovascular events than systolic blood pressure in women: A report from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Circulation. 2005; 112: II-678. Abstract.
26. Herity NA, Lo S, Lee DP, Ward MR, Filardo SD, Yock PG, Fitzgerald PJ, Hunt SA, Yeung AC. Effect of a change in gender on coronary arterial size: a longitudinal intravascular ultrasound study in transplanted hearts. J Am Coll Cardiol. 2003; 41: 1539–1546.
27. New G, Timmins KL, Duffy SJ, Tran BT, O’Brien RC, Harper RW, Meredith IT. Long-term estrogen therapy improves vascular function in male to female transsexuals. J Am Coll Cardiol. 1997; 29: 1437–1444.[Abstract]
28. McCrohon JA, Walters WA, Robinson JT, McCredie RJ, Turner L, Adams MR, Handelsman DJ, Celermajer DS. Arterial reactivity is enhanced in genetic males taking high dose estrogens. J Am Coll Cardiol. 1997; 29: 1432–1436.[Abstract]
29. McCredie RJ, McCrohon JA, Turner L, Griffiths KA, Handelsman DJ, Celermajer DS. Vascular reactivity is impaired in genetic females taking high-dose androgens. J Am Coll Cardiol. 1998; 32: 1331–1335.
30. Herman SM, Robinson JT, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol. 1997; 17: 2004–2009.
31. Lerman A, Cannan CR, Higano SH, Nishimura RA, Holmes DR Jr. Coronary vascular remodeling in association with endothelial dysfunction. Am J Cardiol. 1998; 81: 1105–1109.[CrossRef][Medline] [Order article via Infotrieve]
32. Hoffmann U, Moselewski F, Nieman K, Jang IK, Ferencik M, Rahman AM, Cury RC, Abbara S, Joneidi-Jafari H, Achenbach S, Brady TJ. Noninvasive assessment of plaque morphology and composition in culprit and stable lesions in acute coronary syndrome and stable lesions in stable angina by multidetector computed tomography. J Am Coll Cardiol. 2006; 47: 1655–1662.
33. Holubkov R, Karas RH, Pepine CJ, Rickens CR, Reichek N, Rogers WJ, Sharaf BL, Sopko G, Merz CN, Kelsey SF, McGorray SP, Reis SE. Large brachial artery diameter is associated with angiographic coronary artery disease in women. Am Heart J. 2002; 143: 802–807.[CrossRef][Medline] [Order article via Infotrieve]
34. Khuddus MA, Sizemore BC, Bairey Merz CN, Pepine CJ, McGorray SP, Handberg EM, Smith KM, Sopko G, Sharaf B, Nissen SE, von Mering GO. Coronary atherosclerosis by intravascular ultrasound in women with suspected myocardial ischemia, but no or minimal angiographic disease: A report from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol. 2006; 47: 329A. Abstract.
Related Article:
Reduces Aortic Smooth Muscle Differentiation
Circ. Res. 2006 99: 477-484.
This article has been cited by other articles:
 |
|
 |
|
  D. P. Faxon Women Are Like Men ... Sometimes J. Am. Coll. Cardiol., November 17, 2009; 54(21): 1946 - 1948. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Barton, M. R. Meyer, and E. Haas Hormone Replacement Therapy and Atherosclerosis in Postmenopausal Women: Does Aging Limit Therapeutic Benefits? Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1669 - 1672. [Full Text] [PDF]
|
|
|
|
 |
|
 L. M Gruen and C. J Pepine Raising awareness of angina in women Heart, March 1, 2007; 93(3): 279 - 280. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||